Challenges in the clinical translation of stromal vascular fraction therapy in regenerative medicine

Table 5 Innovative approaches to overcome stromal vascular fraction therapy challenges

Innovative approach	Description	Potential benefits	Current status
CRISPR-based gene editing	Modifying SVF cells to enhance regenerative capabilities and reduce immunogenicity	Improved cell survival and integration. Enhanced therapeutic efficacy	Preclinical research; limited clinical application
Advanced biomaterials	Development of scaffolds and hydrogels to support SVF cell delivery and function	Enhanced cell retention and viability. Controlled release of growth factors	Emerging technologies; ongoing research
Single-cell sequencing	Analyzing individual SVF cells to understand cellular heterogeneity and mechanisms	Identification of key therapeutic cell populations. Personalized treatment strategies	Active research; integration into SVF characterization
Automated isolation systems	Utilizing automated devices for consistent and sterile SVF processing	Standardized cell yields. Reduced contamination risk	Commercially available; increasing adoption
Bioreactor cultivation	Culturing progenitor cells in SVF in bioreactors to scale-up production and enhance cell properties	Large-scale production. Enhanced cell functionality	Pilot studies; early-stage commercialization
Potency assays development	Creating assays to evaluate SVF cell efficacy and functionality before clinical use	Improved quality control. Predictive markers for therapeutic outcomes	Ongoing development; essential for regulatory approval

SVF: Stromal vascular fraction.